These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 14760960

  • 1. A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS.
    Visser LH, Beekman R, Tijssen CC, Uitdehaag BM, Lee ML, Movig KL, Lenderink AW.
    Mult Scler; 2004 Feb; 10(1):89-91. PubMed ID: 14760960
    [Abstract] [Full Text] [Related]

  • 2. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.
    Zivadinov R, Rudick RA, De Masi R, Nasuelli D, Ukmar M, Pozzi-Mucelli RS, Grop A, Cazzato G, Zorzon M.
    Neurology; 2001 Oct 09; 57(7):1239-47. PubMed ID: 11591843
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS.
    Ramo-Tello C, Grau-López L, Tintoré M, Rovira A, Ramió i Torrenta L, Brieva L, Cano A, Carmona O, Saiz A, Torres F, Giner P, Nos C, Massuet A, Montalbán X, Martínez-Cáceres E, Costa J.
    Mult Scler; 2014 May 09; 20(6):717-25. PubMed ID: 24144876
    [Abstract] [Full Text] [Related]

  • 5. Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis.
    Perumal JS, Caon C, Hreha S, Zabad R, Tselis A, Lisak R, Khan O.
    Eur J Neurol; 2008 Jul 09; 15(7):677-80. PubMed ID: 18459972
    [Abstract] [Full Text] [Related]

  • 6. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
    Ravnborg M, Sørensen PS, Andersson M, Celius EG, Jongen PJ, Elovaara I, Bartholomé E, Constantinescu CS, Beer K, Garde E, Sperling B.
    Lancet Neurol; 2010 Jul 09; 9(7):672-80. PubMed ID: 20542736
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis.
    Barnes D, Hughes RA, Morris RW, Wade-Jones O, Brown P, Britton T, Francis DA, Perkin GD, Rudge P, Swash M, Katifi H, Farmer S, Frankel J.
    Lancet; 1997 Mar 29; 349(9056):902-6. PubMed ID: 9093250
    [Abstract] [Full Text] [Related]

  • 9. Comparison of two high doses of oral methylprednisolone for multiple sclerosis relapses: a pilot, multicentre, randomized, double-blind, non-inferiority trial.
    Hervás-García JV, Ramió-Torrentà L, Brieva-Ruiz L, Batllé-Nadal J, Moral E, Blanco Y, Cano-Orgaz A, Presas-Rodríguez S, Torres F, Capellades J, Ramo-Tello C.
    Eur J Neurol; 2019 Mar 29; 26(3):525-532. PubMed ID: 30351511
    [Abstract] [Full Text] [Related]

  • 10. Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis.
    Zivadinov R, Zorzon M, De Masi R, Nasuelli D, Cazzato G.
    J Neurol Sci; 2008 Apr 15; 267(1-2):28-35. PubMed ID: 17945260
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange.
    Abboud H, Petrak A, Mealy M, Sasidharan S, Siddique L, Levy M.
    Mult Scler; 2016 Feb 15; 22(2):185-92. PubMed ID: 25921047
    [Abstract] [Full Text] [Related]

  • 13. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group.
    Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B.
    Lancet; 1997 Mar 01; 349(9052):589-93. PubMed ID: 9057729
    [Abstract] [Full Text] [Related]

  • 14. A transcranial magnetic stimulation study evaluating methylprednisolone treatment in multiple sclerosis.
    Fierro B, Salemi G, Brighina F, Buffa D, Conte S, La Bua V, Piazza A, Savettieri G.
    Acta Neurol Scand; 2002 Mar 01; 105(3):152-7. PubMed ID: 11886356
    [Abstract] [Full Text] [Related]

  • 15. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.
    Cohen JA, Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Mandell BF, Scott TF, Zhang H, Apperson-Hansen C, Beck GJ, Houghtaling PL, Karafa MT, Stadtler M, ACT Investigators.
    Neurology; 2009 Feb 10; 72(6):535-41. PubMed ID: 19204263
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Evaluation of response of multiple sclerosis (MS) relapse to oral high-dose methylprednisolone: usefulness of MS functional composite and Expanded Disability Status Scale.
    Pascual AM, Boscá I, Coret F, Escutia M, Bernat A, Casanova B.
    Eur J Neurol; 2008 Mar 10; 15(3):284-8. PubMed ID: 18290849
    [Abstract] [Full Text] [Related]

  • 18. Follow-up study of MS patients treated with high-dose intravenous methylprednisolone.
    Frequin ST, Lamers KJ, Barkhof F, Borm GF, Hommes OR.
    Acta Neurol Scand; 1994 Aug 10; 90(2):105-10. PubMed ID: 7801735
    [Abstract] [Full Text] [Related]

  • 19. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial.
    Le Page E, Veillard D, Laplaud DA, Hamonic S, Wardi R, Lebrun C, Zagnoli F, Wiertlewski S, Deburghgraeve V, Coustans M, Edan G, COPOUSEP investigators, West Network for Excellence in Neuroscience.
    Lancet; 2015 Sep 05; 386(9997):974-81. PubMed ID: 26135706
    [Abstract] [Full Text] [Related]

  • 20. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
    Sorensen PS, Mellgren SI, Svenningsson A, Elovaara I, Frederiksen JL, Beiske AG, Myhr KM, Søgaard LV, Olsen IC, Sandberg-Wollheim M.
    Lancet Neurol; 2009 Jun 05; 8(6):519-29. PubMed ID: 19409854
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.